MedTrace Logo

EVP-6124 Hepatic Impairment Study

NCT01984736 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2015-01-15

No results posted yet for this study

Summary

The purpose of this study is to assess the pharmacokinetics of EVP-6124 and metabolites after a single oral dose in subjects with mild, moderate and severe hepatic impairment compared with subjects with normal hepatic function.

Conditions

  • Hepatic Impairment

Interventions

DRUG

Experimental: EVP-6124

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • FORUM Pharmaceuticals Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-12-31

Countries

  • Czechia
  • Poland
  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01984736 on ClinicalTrials.gov